Combined fenestrated-branched endovascular repair of the aortic arch and the thoracoabdominal aorta.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
06 2020
Historique:
received: 16 05 2019
accepted: 16 08 2019
pubmed: 23 2 2020
medline: 3 11 2020
entrez: 22 2 2020
Statut: ppublish

Résumé

The aim of our study was to evaluate patients who underwent extensive endovascular aortic stent graft coverage (from the aortic arch to abdominal aorta) in terms of early and midterm clinical outcomes. A retrospective multicenter study was undertaken. All patients were treated with extensive endovascular aortic stent graft coverage with fenestrated and branched endografts at three experienced endovascular centers. Between 2012 and 2017, there were 33 patients (22 male [67%]) treated with a combination of fenestrated-branched stent grafts in the aortic arch and the thoracoabdominal aorta. Most of the patients (20/33 [61%]) had fenestrated-branched endovascular aneurysm repair (fb-EVAR) of the thoracoabdominal aorta as a second-stage procedure after thoracic arch (fb-Arch) repair, 10 had fb-Arch repair as the first procedure, and three patients had a single-stage procedure. The mean age was 67 ± 13 years, and the mean interval between procedures was 13 ± 12 months. For fb-Arch repair, 20 fenestrated and 13 branched devices were used; for fb-EVAR, 23 fenestrated, 5 branched, and 5 composite devices were used. The use of spinal drainage was more common in fb-EVAR (20/33 [61%]). Technical success was 100%. Mean hospital stay was 15 ± 13 days for fb-Arch repair and 12 ± 9 days for fb-EVAR. Two patients died in the hospital after fb-EVAR, resulting in a 30-day mortality of 6% (2/33). No deaths occurred during the fb-Arch repair component or in the single-stage cases. Four patients developed spinal cord injury (12%), 1 had permanent paraplegia (3%), and 2 patients had a neurologic event (1 stroke [3%] and 1 transient ischemic attack [3%]). Six patients (18%) died during a mean follow-up of 23 ± 17 months. The survival at 12 months after the second procedure was 72%, and the freedom from any reintervention was 82%. The 12-month freedom from reintervention was 87% for fb-Arch repair and 81% for fb-EVAR. Extensive endovascular coverage of the aorta for aortic disease seems to be a feasible procedure in experienced centers, with acceptable perioperative morbidity and mortality. Spinal cord ischemia appears acceptable despite extensive aortic coverage.

Identifiants

pubmed: 32081476
pii: S0741-5214(19)32337-7
doi: 10.1016/j.jvs.2019.08.261
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1825-1833

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Nikolaos Tsilimparis (N)

German Aortic Center, Department of Vascular Medicine, University Heart Center, Hamburg, Germany; Department of Vascular Surgery, University Hospital, LMU Munich, Munich, Germany. Electronic address: ntsilimparis@yahoo.com.

Stephan Haulon (S)

Aortic Center, Department of Aortic and Vascular Surgery, Hospital Marie Lannelongue, INSERM UMR_S 999, Universite Paris Sud, Le Plessis-Robinson, France.

Konstantinos Spanos (K)

German Aortic Center, Department of Vascular Medicine, University Heart Center, Hamburg, Germany.

Fiona Rohlffs (F)

German Aortic Center, Department of Vascular Medicine, University Heart Center, Hamburg, Germany.

Franziska Heidemann (F)

German Aortic Center, Department of Vascular Medicine, University Heart Center, Hamburg, Germany.

Timothy Resch (T)

Vascular Center, Department of Thoracic and Vascular Surgery, Skane University Hospital, Malmö, Sweden.

Nuno Dias (N)

Vascular Center, Department of Thoracic and Vascular Surgery, Skane University Hospital, Malmö, Sweden.

Tilo Kölbel (T)

German Aortic Center, Department of Vascular Medicine, University Heart Center, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH